Search the Newsreel

ProMIS Neurosciences Inc (PMN) (Q2 2026) Earnings Call Highlights: Zero ARIA-E Cases and Promising Biomarker Signals in Phase 1b Trial

ProMIS Neurosciences (PMN) reported strong Q2 2026 earnings call highlights, emphasizing zero ARIA-E cases and promising biomarker signals in its Phase 1b PRECISE-AD trial. The company maintains a strong cash position of $53.4 million, funding operations through 2027, and is advancing its pipeline candidates …

Promis Neurosciences (NASDAQ:PMN) Issues Quarterly Earnings Results, Beats Estimates By $0.10 EPS

Promis Neurosciences (NASDAQ:PMN) reported its quarterly earnings, beating analyst estimates by $0.10 with a loss of $1.28 per share. The company highlighted encouraging interim safety results for its Alzheimer's candidate PMN310, with promising biomarker data suggesting target engagement. Promis Neurosciences expects its current cash …

Earnings call transcript: ProMIS Neurosciences posts strong cash position in Q2 2026

ProMIS Neurosciences reported a strong cash position of CAD 53.4 million at the end of Q2 2026, sufficient to fund operations through 2027 and a crucial data readout in Q1 2027. The clinical-stage biotech company shared positive interim safety and biomarker data from its …

ProMIS Neurosciences Reports Q2 2026 Results: Full Earnings Call Transcript

ProMIS Neurosciences (PMN) extends cash runway with $70.1M PIPE amid higher R&D

ProMIS Neurosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

ProMIS Neurosciences announced its Q2 2026 financial results, ending the quarter with $53.4 million in cash, expected to fund operations through 2027. The company also provided positive blinded six-month interim safety and biomarker results from its PRECISE-AD Phase 1b trial for PMN310 in early …

ProMIS Neurosciences Inc. Q2 2026: Net loss $(11.73)M, Diluted EPS $(1.28) — 10-Q Summary

ProMIS Neurosciences Inc. reported a net loss of $(11.73)M for Q2 2026, with a diluted loss per share of $(1.28), an increase in net loss compared to Q2 2025 but an improvement in diluted EPS. The company generated no product revenue. Key highlights include …

ProMIS Neurosciences Inc (PMN) Earnings Forecast: Future EPS & Revenue Growth Estimates

Promis Neurosciences (NASDAQ:PMN) Receives Consensus Rating of "Moderate Buy" from Analysts

Promis Neurosciences (NASDAQ:PMN) has received a consensus "Moderate Buy" rating from eight brokerages, with an average 12-month price target of $31.50. Despite this positive outlook, the company reported a quarterly loss of $1.26 per share, missing consensus estimates, and analysts anticipate a full-year loss …

ProMIS Neurosciences Inc (PMN) Stock News Today

This article provides an update on ProMIS Neurosciences Inc (PMN) stock, noting a recent increase of 10.35%, bringing its share price to 14.710 USD. The platform, TradingKey, states that more news, earnings reports, analyst ratings, and key developments for PMN are coming soon. The …

Insider at ProMIS Neurosciences (PMN) buys 2,280 common shares

Johanne Kaplan, Chief Development Officer of ProMIS Neurosciences Inc. (PMN), purchased 2,280 common shares at $13.30 each on August 5, 2026. This open market transaction increased her direct holdings to 6,221 common shares. The filing was classified as neutral in impact and positive in …

Promis Neurosciences (PMN) Projected to Post Earnings on Thursday

Promis Neurosciences (PMN) is expected to report its Q2 2026 earnings before market open on Thursday, August 13th, with analysts forecasting a loss of $1.3786 per share. This follows a larger-than-expected loss in the previous quarter. Despite mixed analyst views, the company holds a …

ProMIS schedules 4:30 p.m. webcast for Aug. 13 update

ProMIS Neurosciences (Nasdaq: PMN) will report its second-quarter 2026 financial results and provide a business update on August 13, 2026. The company will host an investor conference call and webcast on the same day at 4:30 p.m. Eastern Time. U.S. investors can dial 1-877-407-9208, …

Janus Henderson Group PLC Acquires New Position in Promis Neurosciences $PMN

ProMIS Neurosciences to report Q2 results, host investor call and webcast

ProMIS Neurosciences will release its Q2 results for the period ending June 30, 2026, on August 13, 2026. The company will also host an investor conference call and webcast on the same day at 4:30 p.m. ET to discuss the results. This news brief …

ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026

ProMIS Neurosciences Inc. will report its second-quarter 2026 financial results and provide a corporate update on August 13, 2026. The company will host an investor conference call and webcast on the same day at 4:30 p.m. ET to discuss these results and updates. ProMIS …

PMN|ProMIS Neurosciences Inc|Price:13.720|Chg%:-1.200

This article provides a comprehensive stock analysis of ProMIS Neurosciences Inc (PMN), highlighting its strong fundamentals and high growth potential. The company's valuation is considered fair, and institutional ownership is notably high. Analysts have issued "Buy" ratings, projecting a significant upside for the stock …

Chardan Adjusts Price Target on ProMIS Neurosciences to $33 From $20, Maintains Buy Rating

Chardan has increased its price target for ProMIS Neurosciences (PMN.TO) to $33 from $20, while reiterating a Buy rating on the stock. This adjustment reflects a more optimistic outlook on the company's future performance.

Maxim Group Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Maintains Target Price $35

Maxim Group has reiterated its Buy rating for ProMIS Neurosciences (PMN.US) and maintained its price target of $35. This indicates continued confidence from the firm in the company's prospects.

Promis Neurosciences (NASDAQ:PMN) Upgraded at Chardan Capital

Promis Neurosciences $PMN Stock Holdings Boosted by Ally Bridge Group NY LLC

Yu Fan Buys New Stake in Promis Neurosciences $PMN

ProMIS Neurosciences (PMN) Surges 21.3% Pre-Market Ahead of Earnings; Valuation Reflects High Growth Expectations

ProMIS Neurosciences (PMN) experienced a 21.3% pre-market surge ahead of its earnings announcement, driven by investor optimism despite being a clinical-stage biotech with no current sales. The company's valuation is speculative, based on future growth potential in neurodegenerative disease therapeutics, rather than traditional financial …

ProMIS jumps on trial data for Alzheimer’s drug (PMN:NASDAQ)

ProMIS Neurosciences (PMN) share price increased following the release of interim data from an early-stage trial for its Alzheimer's drug, PMN310. The positive results led Guggenheim to raise its price target for the Canadian company.

ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease

ProMIS Neurosciences will host a webinar on July 28, 2026, to discuss 6-month blinded interim data from its PRECISE-AD Phase 1b trial of PMN310 in early Alzheimer's disease. Key Opinion Leaders Dr. Will Mantyh and Dr. Michael Weiner will join company leadership to review …

ProMIS Alzheimer's Drug Shows Strong Safety Profile Midway Through Trial

ProMIS Neurosciences' Alzheimer's drug, PMN310, has shown a strong safety profile midway through its Phase 1 clinical trial. The study found no evidence of amyloid-related imaging abnormalities (ARIA), a common side effect in other amyloid-targeting Alzheimer's treatments. This positive safety data suggests PMN310 could …

ProMIS Neurosciences Shares Climb on Positive Interim Alzheimer’s Trial Safety Results

ProMIS Neurosciences (NASDAQ: PMN) shares rose 13% after reporting positive six-month interim safety and biomarker data from its PRECISE-AD Phase 1b study for Alzheimer's treatment PMN310. The study showed a strong safety profile with no serious adverse events and no ARIA-E cases, suggesting the …

ProMIS Neurosciences reports no ARIA‑E and favorable 6‑month biomarker trends for PMN310; 12‑month topline due Q1 2027

ProMIS Neurosciences released a six-month interim report for PMN310, showing no ARIA-E and low total ARIA (4.4%), with favorable biomarker trends. The trial is blinded and ongoing, with unblinded 12-month topline results, including efficacy data, anticipated in Q1 2027. PMN310 is designed to specifically …

ProMIS Neurosciences stock jumps on trial safety data

ProMIS Neurosciences Inc. (NASDAQ:PMN) stock jumped 13% after reporting positive blinded six-month interim safety and biomarker data for PMN310 in its PRECISE-AD Phase 1b Alzheimer’s disease trial. The trial showed no amyloid-related imaging abnormalities-edema (ARIA-E) and low levels of ARIA-H, with no serious adverse …

ProMIS Neurosciences (Nasdaq: PMN) reports positive six-month PMN310 Alzheimer’s trial data

ProMIS Neurosciences (Nasdaq: PMN) announced positive blinded six-month interim safety and biomarker data from its Phase 1b PRECISE-AD trial for PMN310 in early Alzheimer's disease. The data showed a favorable safety profile with no ARIA-E cases and a low rate of total ARIA, even …

ProMIS Neurosciences Inc (PMN) Income Statement

This article provides the quarterly and annual income statements for ProMIS Neurosciences Inc (PMN), detailing financial performance metrics such as total revenue, operating expenses, and net income. It includes data from FY2012Q1 to FY2026Q1, highlighting negative net income and operating profit over recent periods. …

Two Alzheimer’s researchers join ProMIS webinar on blinded trial data

ProMIS Neurosciences will host a webinar on July 28, 2026, to discuss six-month blinded interim data from its PRECISE-AD Phase 1b trial of PMN310, its lead Alzheimer's candidate. The webinar will feature company executives, Dr. Will Mantyh, and Dr. Michael Weiner, who will discuss …